CD274 and neoplasm: The advent of immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 blocking antibodies, has revolutionized the treatment of lung cancer by reactivating tumor‐infiltrating lymphocytes (TILs) and augmenting anti‐tumor immunity [3, 4].